Search

Author/Creator Bezecny, Pavel

1. Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. (December 2022)

Authors:
Bahl, Amit; Wilson, William; Ball, Jessica; Renninson, Emily; Dubey, Sidharth; Bravo, Alicia; Foulstone, Emily; Spensley, Saiqa; Bowen, Rebecca; Mansi, Janine; Waters, Simon; Riddle, Pippa; Wheatley, Duncan; Stephens, Peter; Bezecny, Pavel; Madhusudan, Srinivasan; Verrill, Mark; Braybrooke, Jerem...
Journal:
Breast
Issue:
Volume 66(2022)
Page Start:
69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Issue 3 (March 2020)

Authors:
Jones, Robert H; Casbard, Angela; Carucci, Margherita; Cox, Catrin; Butler, Rachel; Alchami, Fouad; Madden, Tracie-Ann; Bale, Catherine; Bezecny, Pavel; Joffe, Johnathan; Moon, Sarah; Twelves, Chris; Venkitaraman, Ramachandran; Waters, Simon; Foxley, Andrew; Howell, Sacha J
Journal:
Lancet oncology
Issue:
Volume 21:Issue 3(2020)
Page Start:
345
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Issue 7 (July 2022)

Authors:
Howell, Sacha J; Casbard, Angela; Carucci, Margherita; Ingarfield, Kate; Butler, Rachel; Morgan, Sian; Meissner, Magdalena; Bale, Catherine; Bezecny, Pavel; Moon, Sarah; Twelves, Chris; Venkitaraman, Ramachandran; Waters, Simon; de Bruin, Elza C; Schiavon, Gaia; Foxley, Andrew; Jones, Robert H
Journal:
Lancet oncology
Issue:
Volume 23:Issue 7(2022)
Page Start:
851
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. (December 2021)

Authors:
El Badri, Salma; Tahir, Bilal; Balachandran, Kirsty; Bezecny, Pavel; Britton, Fiona; Davies, Mark; Desouza, Karen; Dixon, Simon; Hills, Daniel; Moe, Maung; Pigott, Thomas; Proctor, Andrew; Shah, Yatri; Simcock, Richard; Stansfeld, Anna; Synowiec, Alicja; Theodoulou, Marianna; Verrill, Mark; Wadha...
Journal:
Breast
Issue:
Volume 60(2021)
Page Start:
199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search